Opus Genetics, Inc. Billed Contracts Receivable
Opus Genetics, Inc. (IRD) had Billed Contracts Receivable of $1.50 million as of 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Notes › Receivables
us-gaap:BilledContractReceivables · last filed 2020-02-21
- 2019-12-31: Billed Contracts Receivable $1.50M.
- 2019-09-30: Billed Contracts Receivable $1.50M.
- 2019-06-30: Billed Contracts Receivable $1.50M.
- 2019-03-31: Billed Contracts Receivable $2.85M.
| Period end | Billed Contracts Receivable |
|---|---|
| 2019-12-31 | $1.50M 10-K · filed 2020-02-21 |
| 2019-09-30 | $1.50M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.50M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $2.85M 10-Q · filed 2019-05-10 |
| 2013-12-31 | $56.05K 10-K · filed 2014-03-21 |
| 2013-09-30 | $56.05K 10-Q · filed 2013-11-13 |
| 2013-06-30 | $56.05K 10-Q · filed 2013-08-12 |
| 2013-03-31 | $56.05K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $56.05K 10-K · filed 2013-03-22 |
| 2012-09-30 | $56.05K 10-Q · filed 2012-11-08 |
| 2010-06-15 | $56.05K 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |